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Purpose. To evaluate the relationship between self-reported vision-related quality of life (VRQL) and visual ﬁeld (VF) loss in people
from glaucoma clinics.Methods.A postal survey using the National Eye Institute Visual Function Questionnaire (NEI VFQ-25) was
administered to people with a range of VF loss identiﬁed from a UK hospital-based glaucoma service database. Trends were
assessed in a composite score from NEI VFQ-25 against better-eye mean deviation (BEMD) using linear regression and a
spline-ﬁtting method that can highlight where a monotonic relationship may have diﬀerent stages. Results. A total of 636
patients (median [interquartile range] BEMD −2.1 [−5.2, −0.4] dB, median age 70 [60, 77] years) were analysed. Analysis of
trends in the data revealed an average patient loses approximately 2 units (out of 100) on NEI VFQ-25 for every loss of 1 dB
(BEMD) as VF defects ﬁrst become bilateral, up to BEMD −5 dB. NEI VFQ-25 deterioration then appears to slow before a more
rapid phase of change (4–5 units per 1 dB loss) after BEMD worsens beyond −15 dB. Conclusions. Relationship between decline
in VRQL and VF worsening in glaucoma is unlikely to be linear; it more likely has diﬀerent phases, and these should be further
explored in longitudinal studies.
1. Introduction
Loss of visual ﬁeld (VF) sensitivity is a hallmark in patients
with glaucoma [1]. VF loss can pose a signiﬁcant threat to
patients’ everyday functioning and quality of life. It is often
the case that patients report greater diﬃculty in performing
vision-related tasks as the severity of their glaucoma
increases and VF worsens [2–7]. However, it is not uncom-
mon for the eﬀects of glaucoma to go undetected by the
patient [1, 8]. For example, many performance-based studies
demonstrate that glaucoma patients can perform within the
normal expected range, even in cases of advanced VF loss
[9–13]. Conversely, other evidence suggests that even mild
or moderate disease may have an impact on the patient’s
quality of life [14].
Assessment of vision-related quality of life (VRQL) typi-
cally involves self-reported responses to questionnaires. These
questionnaires, also referred to as “instruments,” feature
items whereby patients mainly document the extent to which
they struggle to complete routine tasks. The National Eye
Institute Visual Function Questionnaire (NEI VFQ-25) was
developed more than 15 years ago [15] and has been widely
used in ophthalmology research as a measure of VRQL. This
instrument was used in a landmark report revealing the asso-
ciation between VF loss and health-related quality of life in
glaucoma [7] and has been widely used in other cross-
sectional studies [3–6, 14, 16, 17]. However, these studies
report only a modest relationship between VRQL and VF
damage. More recently, longitudinal studies of glaucoma
patient cohorts have highlighted NEI VFQ-25 scores to be
impacted by location and speed of VF loss [18–20].
Association between VF loss and worsening of VRQL
reported in the literature mainly implies that the relationship
is a linear one [7, 14, 18, 19]. That is, VRQL constantly
declines as the VF worsens. In fact, the relationship between
loss of VRQL and VF worsening is likely better described as a
monotonic one. In other words, whilst VRQL never improves
as the VF worsens, the decline could have slow or rapid stages
or even remain relatively constant for a phase. This idea,
relatively unexplored, is the subject of our report.
Patients with glaucoma are typically asymptomatic in the
early stages of the disease process. Any change in VF status
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may be compensated for by good binocular vision or is sim-
ply not noticed. As VF loss becomes symptomatic, a patient is
more likely to self-report an impact on VRQL, but in turn,
patients may adapt to their vision loss. Indeed, there is some
evidence that behavioural adaptions, such as adjusted head
and eye movements, can help glaucoma patients compen-
sate for their vision loss when completing everyday tasks
[9, 10, 21–25]. Eventually as glaucoma worsens, more
complete binocular VF loss will impact on legality of driv-
ing and restrict mobility and conﬁdence [24–31].
Patients with more advanced glaucoma report signiﬁ-
cantly worse scores on the NEI VFQ-25 compared to
their better-sighted peers. In a recent cross-sectional analysis
of an established cohort of 233 patients from the Early
Manifest Glaucoma Trial (EMGT) [32] (trial registration:
NCT00000132), Peters et al. hinted at the idea of accelerated
worsening of VRQL once patients reach a certain VF thresh-
old in their least-aﬀected (or better) eye [33]. This evidence
suggests a “tipping point” after which each decibel of VF loss
will have more severe consequences for patients’ VRQL. This
observation is worth further study. Here, we investigate the
relationship between VRQL (using NEI VFQ-25 scores)
and a summary measure of VF loss amongst a spectrum of
disease severity in a large number of patients from a glau-
coma clinic. Speciﬁcally, we consider that the rate of decline
in VRQL may not simply be a linear process and we look
for statistical evidence of diﬀerent phases of decline or
periods where there might be more or less rapid reduction
as the VF worsens.
2. Materials and Methods
This study took advantage of anonymised patient data col-
lected as part of an investigation of conducting a randomised
controlled trial for glaucoma screening in theUnitedKingdom
(UK) [34]. The data, collected from a cross-sectional postal
survey, is described in detail elsewhere [35], butwe summarise
it here too.
Potential participants were identiﬁed by an ophthalmolo-
gist from an electronic patient record (Medisoft, Leeds, UK)
of VFs at a hospital-based glaucoma service in London
(Moorﬁelds Eye Hospital NHS Foundation Trust). Recruit-
ment criteria required potential patients to have at least two
entries in the database having undergone VF testing on a
Humphrey visual ﬁeld analyser (HFA; Carl Zeiss Meditec,
CA, USA) between January 2007 and September 2009. To be
included, patients were required to have reproducible HFA
24-2 (SITA Standard) VF defects in both eyes at the two most
recent visits as determined by the glaucoma hemiﬁeld test
(GHT) [36]. The GHT results had to be “borderline” or “out-
side normal limits” as recorded in the electronic patient
record on both occasions. A total of 1349 patients were con-
sidered suitable for study recruitment. Ethical approval was
granted and the study adhered to the Declaration of Helsinki.
Questionnaires were posted to all patients considered
suitable for the study in March 2010. Included in the survey
was the vision-speciﬁc patient-reported outcome measure,
the NEI VFQ-25 [15]. This instrument consists of 25 items
across 12 subscales, where 11 constructs are vision-related
(general vision, ocular pain, near activities, distant activities,
social functioning, role diﬃculties, mental health, depen-
dency, driving, colour vision, and peripheral vision) and
one construct regarding general health. A reminder letter
was sent two weeks after initial contact. The return of com-
pleted questionnaires was considered as consent to take part
in the study. A total of 656 questionnaires were returned.
We used HFA mean deviation (MD) in the least-aﬀected
eye (best eye MD; BEMD) recorded at the most recent clini-
cal visit when the questionnaire was administered as our sur-
rogate measure of VF loss. The MD is conventionally used in
the clinic and in clinical trials; it is a summary measure of the
overall reduction in VF sensitivity relative to a group of
healthy age-matched observers with more negative values
indicating more vision loss. We used the BEMD since this
best reﬂects the patients’ VF morbidity [37]. Numeric
responses on the NEI VFQ-25 were recoded in line with the
scoring guidelines [15]. Each item is converted into a value
ranging from 0 to 100 where higher scores indicate greater
VRQL and lower scores are indicative of poorer VRQL. A
composite score for VRQL was then calculated by averaging
all vision-related subscales. In cases where more than 5% of
the questionnaire data were missing, or where subscale scores
were unable to be calculated due to insuﬃcient data,
responses were excluded from our analysis. In line with scor-
ing guidelines, patients who had never driven a car had
responses coded as “missing” for the driving subscale [15].
A total of 636 patients with complete NEI VFQ-25 and
BEMD data were used for our analysis. No other data, apart
from age (years) at the time of the most recent VF, was
considered.
We explored the relationship between BEMD and NEI
VFQ-25 using the freeknotspline package in the statisti-
cal programming language R (http://www.R-project.org).
This package ﬁts free-knot splines to data with one indepen-
dent variable and one dependent variable [38, 39]. This tech-
nique will automatically highlight phases where a monotonic
relationship between two variables may change. The points
where the phases (segments) connect are called the knots of
the spline. The knots can be determined a priori or by allow-
ing the data to dictate areas where change occurs. A knot-
search algorithm is provided for the case where the number
of knots is not known in advance, as with our data. We can
then compare the model that describes this relationship
against a linear relationship (using ordinary least squares
regression (OLSR)) by considering the Akaike information
criterion (AIC); this is a measure of the relative quality of sta-
tistical models for a given set of data and provides a means
for model selection [40]. Phases in the relationship between
BEMD and NEI VFQ-25 identiﬁed by this approach were
then further analysed using linear OLSR where a series of
separate OLSR lines are ﬁtted to appropriate ranges of
BEMD. All this subsequent analysis, including plotting the
data, was carried out in R (http://www.R-project.org).
3. Results and Discussion
Median (interquartile range (IQR)) age of the 636 patients
analysed was 70 (60, 77) years. Median (IQR) BEMD
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was −2.1 (−5.2, −0.4) dB and worst eye MD was −5.5
(−11.3, −2.3) dB. Median (IQR) composite score on the
NEI VFQ-25 was 89 (74, 95) points. The majority of
patients (97%) scored their general health to be good or
better on the general health item of the NEI VFQ-25.
Figure 1 shows the distribution of patients’ BEMD score
against composite scores from the NEI VFQ-25. The red line
(left-hand side plot) gives the best-ﬁtting linear OLSR line
(red line). This model assumes a linear association between
BEMD and the NEI VFQ-25. The blue line (right-hand side
plot) shows the automatically chosen penalised spline model
which had two knots with a polynomial of degree 3. The AIC
index for the linear and spline models was 3601.7 and 3596.0,
respectively. In simple terms, the AIC index indicates stron-
ger evidence for a preference of one model over another (the
lower the better). There is some debate in the applied statis-
tics literature about the meaning of small diﬀerences in
AIC, but differences > 5 (as with our data) indicate that the
model with the lower AIC is likely to be more informative
[41]. For our purposes, this statistical interrogation of the
relationship mainly suggests demarcated phases where NEI
VFQ-25 deteriorates with more or less acceleration as a
patient’s BEMD worsens. On inspection, there seems to be
three phases in the association. For BEMD up to about
−5 dB, there is a distinct slope followed by a phase (between
−5 dB and −15dB) where the line ﬂattens before it becomes
much steeper again (worse than −15 dB). Three OLSR lines
were ﬁtted to these three phases, and the results along with
95% conﬁdence limits are shown in Figure 2 with model
parameters given in Table 1. Simply put, the average patient
loses about 2 units (out of 100) on the NEI VFQ-25 for every
loss of 1 dB (BEMD) as their glaucomatous VF loss becomes
bilateral, up to −5 dB. Worsening on the NEI VFQ-25 then
appears to slow down: the average patient loses about 1 unit
(out of 100) on theNEIVFQ-25 for every loss of 1 dB (BEMD)
from −5 to −15 dB. Finally, a more rapid phase of deteriora-
tion in VRQL seems to occur: after the BEMD worsens to
around −15 dB, the average patient starts to lose 4 to 5 units
on the NEI VFQ-25 for every remaining loss of 1 dB (BEMD).
4. Discussion
Economists anecdotally refer to bankruptcy happening in
two stages—gradually then suddenly [42]. Hence, it is a
monotonic process but not necessarily a linear one. In this
study, we provide some evidence that this is what happens
in patients’ perception of their VRQL as their glaucomatous
VF worsens in their better eye over time. Rather than a linear
decline, we suggest that there are phases of change attributed
to progression in the VF in the least-aﬀected eye. The phases
illustrated in the statistical associations we report make clin-
ical sense. As the better-seeing eye gets measurable VF loss
(bilateral disease), the previously asymptomatic patient may
begin to notice the impact of scotoma as they perform visual
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Figure 1: Points represent scores on NEI VFQ-25 compared to BEMD (dB) for 636 patients. The use of linear (red line) and spline (blue line)
regression modelling assessing trend in relationship between the two variables.
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tasks. A phase of adaptation to this loss then might likely pre-
cede another phase where advanced loss in both eyes really
impacts on VRQL. Our evidence is not strong; it is merely
based on a cross-sectional survey of people from glaucoma
clinics with no supplementary clinical information. Yet our
results support a concept that ought to be tested with other
datasets or longitudinal studies. Better knowledge on how
visual function decline may accelerate at diﬀerent stages of
the disease process would be useful for the clinical manage-
ment of patients and also for health economists as they deter-
mine better utilities for evaluating glaucoma treatments.
Our ﬁndings add to the current understanding of how
patients perceive their diﬃculty living with glaucoma. VRQL
deteriorates as glaucoma worsens and our data supports
this. This association is not particularly a strong one. For
example, the R-squared (%) for the linear association
between VRQL and BEMD data is 21% suggesting that only
part of the variance in VRQL is explained by the VF. More-
over, it is quite remarkable how some patients with BEMD
worse than −20 dB (top left hand corner of graph depicted
in Figure 2) report VRQL to be the same or better than
many patients with a BEMD of 0 dB or higher. This observa-
tion coincides with the ﬁndings of others indicating only a
modest relationship between NEI VFQ-25 scores and VF
status [3–6, 14, 16, 17]. Our statistical treatment of the large
cross-sectional data implies that this weak association may
behave diﬀerently at diﬀerent stages of BEMD severity and
this is new knowledge. Our ﬁndings give some weight to
the idea that the speed at which VRQL declines may alter
during diﬀerent phases of the disease and that speciﬁc
markers for BEMD could indicate change points in patient-
reported functional ability.
Our observations of diﬀerent phases of association
between VRQL and BEMD are supported by the results from
a twenty-year follow-up of patients in the EMGT [33]. In a
cross-sectional analysis of this cohort of 233 patients, Peters
et al. found a signiﬁcant diﬀerence in Rasch-calibrated scores
on the NEI VFQ-25 for patients with BEMD worse than
−18 dB and those with BEMD better than −18dB. In cases
where BEMD was worse than −18 dB, patients’ scores on
the NEI VFQ-25 did not exceed 70 out of 100. This suggests
diﬀerent phases in the relationship between BEMD and the
NEI VFQ-25, with a threshold where impact of VF loss accel-
erates. A strength of this study is that a wide range of glau-
coma severity was analysed, whereas other studies consider
only patients with early glaucomatous damage [3, 14].
In addition to supporting the concept of a nonlinear rela-
tionship between VRQL and BEMD, our results also support
recent ﬁndings regarding the impact of glaucoma on VRQL
in the earlier stages of the disease. Our results indicate that
a 1 dB decline in BEMD is associated with an average reduc-
tion of 2.3 units on the NEI VFQ-25 for patients with BEMD
between +2dB and −5 dB. This ﬁnding is similar to that of a
longitudinal study by Alqudah et al. [14] who found an
association between scores on the NEI VFQ-25 and BEMD
in the early stages of glaucoma. Their study was restricted
to patients with BEMD between approximately +2.5 dB
and −5 dB, and they reported a decline of 0.5 units on the
NEI VFQ-25 for each 1 dB reduction.
Our ﬁndings become important when considering treat-
ment options for patients with advanced stage glaucoma. It
is evident that patients’ VRQL reduces rapidly once BEMD
loss becomes advanced. Decline in VRQL is approximately
four times faster than that in the previous stages of the dis-
ease after patients’ vision deteriorates beyond −15dB. This
threshold may have important clinical implications when
treating patients in the advanced stages of the disease. Due
to the potential for fast decline in VRQL, this point could
be used to guide potential intervention options when treating
patients with advanced glaucoma. The suggestion has been
made that more research is needed in order to determine
the best treatment option for advanced glaucoma [43], and
this is currently under investigation in a randomised clinical
trial [44]. Our results may also have implications for those
developing utilities for health economic models for glaucoma
treatments [45].
There are some strengths to our study. The sample size
was large and we took advantage of a large database of
recorded VF data. These data represent unselected people
in glaucoma clinics that are receiving routine care, and there-
fore, estimates are directly meaningful to “real-world” prac-
tice. In addition, the patients in this study had a wide range
of glaucoma severity. However, the proportion of patients
with early VF damage was greater than the advanced cases
and this could be perceived as a limitation.
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Figure 2: Fitting of three OLSR lines with 95% conﬁdence limits for
each phase of decline in VRQL. Points represent scores on the NEI
VFQ-25 and BEMD in 636 patients. The green phase shows the
slowest decline in NEI VFQ-25 score; the yellow line shows
quicker decline where NEI VFQ-25 scores reduce 2 times faster
than that in the green phase. The red line shows decline on NEI
VFQ-25 as about four times quicker than that in the green phase.
Table 1: Relationship between decline in NEI VFQ-25 score for
piecewise regression analysis for each 1 dB decline in BEMD score.
BEMD (dB) N
Slope (95% conﬁdence
interval)
Standard
error
p
value
+2 to −5
(yellow)
475 2.3 (1.5, 3.0) 0.40 <0.001
−5 to −15
(green)
132 1.1 (−0.3, 2.5) 0.70 0.14
<−15 (red) 29 4.6 (1.2, 8.0) 1.64 0.009
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Our investigation also had some limitations. The data
used is cross-sectional and so we only consider patients’
VRQL and VF loss at a single time point. Moreover, mea-
sures of VRQL are self-reported. We are, for example, unable
to account for the rate at which patients’ VF defect has
progressed, and this has been shown to inﬂuence VRQL
[19, 46, 47]. A better study design would use longitudinal
data [18, 19]. Additionally, our study has the potential for
response bias (49% response rate). However, given the adop-
tion of a postal survey design and adherence to an ethical
study protocol, a full response rate would be unlikely. As
VF data were unavailable for those who did not choose to
participate, we were not able to consider the characteristics
of nonresponders. Nevertheless, 49% is higher than the
response rates observed in studies using a similar design
[48]. We did not have information on race, educational level,
and marital status, and these factors can inﬂuence quality of
life. In addition, there may have been a large gap in time
between patient’s latest VF data and when the completed
NEI VFQ-25 was returned. The main problem with the
design of this study is the absence of any clinical indictors
on the eyes other than the VFs. We did not, for example, have
information on coexisting cataract or detailed treatment his-
tory. Additionally, for this unselected sample, we did not
have measures of visual acuity. A further disadvantage of
our analysis is that we did not use a Rasch model to analyse
the results of the NEI VFQ-25, whereas studies similar to
ours have done this [18, 19, 33].
Our study opens up avenues for future research into the
association between VRQL and clinical measures of vision
loss. We found that the rate of decline in glaucoma patients’
VRQL begins to slow after BEMD is reduced to −5 dB. This
slow decline in NEI VFQ-25 scores remains evident until
BEMD is reduced to −15dB, where rapid decline occurs.
More research is needed in order to understand what factors
can inﬂuence the rate at which patient VRQL declines. A
well-designed prospective study should consider VRQL in
people at this moderate or middle stage of disease and con-
sider how they might be adapting to their VF loss. Moreover,
we used only one measure of VRQL, namely the NEI VFQ-
25. Previous research has indicated that no single instrument
covers all aspects of patients’VRQL [49]. As such, replication
of this study assessing responses on an instrument speciﬁc to
glaucoma would be an interesting addition to the literature.
5. Conclusion
In conclusion, the relationship between VRQL and BEMD is
a weak monotonic one. However, we provide some evidence
to suggest that this relationship may not be a linear one. The
speed at which VRQL declines might better be described as
gradually, where patients experience a period of adaption to
their vision loss, and then suddenly, once patients’ functional
abilities become signiﬁcantly impaired.
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